Article
Virology
Jing Zeng, Xiuqun Zhang, Lin Jia, Yongfeng Wu, Yakun Tian, Yulin Zhang
Summary: Both LMR (lymphocyte-to-monocyte ratio) and PLR (platelet-to-lymphocyte ratio) have been found to be prognostic indicators in patients with AR-DLBCL (AIDS-related diffuse large B-cell lymphoma). Lower LMR is independently associated with poorer overall survival in these patients.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Medicine, Research & Experimental
Wei Yu, Zhiluo Yang
Summary: Circulating neutrophils are increased and lymphocytes are decreased in DLBCL patients, leading to higher NLR. Higher neutrophils and NLR are closely associated with poorer DFS, while higher NK cells before treatment predict better therapeutic outcome.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Review
Oncology
Maria Huguet, Jose-Tomas Navarro, Jose Molto, Josep-Maria Ribera, Gustavo Tapia
Summary: Non-Hodgkin lymphoma (NHL) is a common HIV-related neoplasm, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype. DLBCL in people with HIV presents with aggressive characteristics. The introduction of combined antiretroviral therapy (cART) and the use of cART with chemotherapy have significantly improved the prognosis for people with HIV and DLBCL, approaching that of the general population.
Article
Oncology
Zanzan Wang, Jiawei Zhang, Shuna Luo, Xiaoying Zhao
Summary: The study evaluated the role of systemic immune-inflammation index (SII) in predicting survival for patients with diffuse large B cell lymphoma (DLBCL). SII was found to be a powerful prognostic tool, with higher SII values indicating poorer prognosis and potentially aiding in identifying high-risk patients among those with the same international prognostic index (IPI).
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Kawa Muhamedamin Hasan, Ahmed Yassin Elmeshhedany
Summary: The study found that LMR, RDW, and NLR were associated with some characteristics of DLBCL patients, but did not have predictive value for patient survival.
CELLULAR AND MOLECULAR BIOLOGY
(2021)
Article
Surgery
Zhuoya Zhou, Jing Chen
Summary: This study is the largest population-based study to date on independent prognostic factors of CCSV-DLBCL. Age, race, surgical resection, radiation, and chemotherapy are closely associated with patients' survival outcomes.
ASIAN JOURNAL OF SURGERY
(2023)
Review
Biochemistry & Molecular Biology
Xiao-jie Liang, Xin-yu Song, Jia-lin Wu, Dan Liu, Bing-yu Lin, Hong-sheng Zhou, Liang Wang
Summary: This article provides an overview of the research advances in DLBCL prognostic biomarkers using a multi-omics approach. It emphasizes the urgent need for highly specific and sensitive biomarkers to predict the therapeutic response of DLBCL and assess patient benefit from systemic chemotherapy. The use of systems biology in DLBCL research is highlighted for its comprehensive quantification and identification of biomarkers and its potential to address major biological problems with high accuracy and sensitivity.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Hematology
Shu-Yun Ma, Xiao-Peng Tian, Jun Cai, Ning Su, Yu Fang, Yu-Chen Zhang, Jin-Ni Wang, Robert Peter Gale, Qing-Qing Cai
Summary: A prognostic score for DLBCL patients based on infiltrating immune cells was constructed, showing that the immune risk score is an accurate and independent survival predictor in DLBCL patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Feiqiong Gao, Jianlai Hu, Jiawei Zhang, Yang Xu
Summary: Low LMR in peripheral blood is associated with poor prognosis in lymphoma patients, including HL, NHL, and its subtypes. Additionally, low LMR is related to higher LDH, advanced tumor staging, and IPI score.
Article
Cell Biology
Wei Wang, Shi-wen Xu, Ya Teng, Min Zhu, Qun-yi Guo, Yuan-wen Wang, Xin-Li Mao, Shao-wei Li, Wen-da Luo
Summary: The study showed that a significant portion of pyroptosis-related genes are dysregulated in DLBCL and are associated with prognosis. Three distinct pyroptosis-related clusters were identified in DLBCL patients, showing significant differences in prognosis, biological processes, clinical characteristics, chemotherapeutic drug sensitivity, and tumor immune microenvironment. A risk score signature was developed to effectively differentiate high-risk and low-risk patients, and a nomogram incorporating this signature with clinical indicators demonstrated excellent predictive ability for DLBCL patient prognosis.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Medicine, General & Internal
Yu-Qing Chen, Zi-Fan Yue, Sai-Nan Chen, Fei Tong, Wei-Hua Yang, Rui-Li Wei
Summary: This study is the largest population-based case series of orbital diffuse large B-cell lymphoma (DLBCL) to date, and it found that age at diagnosis, marital status, absence of chemotherapy or radiotherapy, and tumor stage were all correlated with worse prognosis.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Jincai Yang, Lili Yu, Jianchen Man, Huiling Chen, Lanxia Zhou, Li Zhao
Summary: This study focused on the role of tumor-infiltrating immune cells in the prognosis of DLBCL and constructed a predictive model that can effectively predict the prognostic outcome of patients with DLBCL. The reliability of the model was validated in two data sets. This research sheds light on the importance of considering immune cells in tumor prognosis.
Article
Immunology
Xiaoxuan Wang, Yaxiao Lu, Ziyi Liu, Yidan Zhang, You He, Cong Sun, Lanfang Li, Qiongli Zhai, Bin Meng, Xiubao Ren, Xudong Wu, Huilai Zhang, Xianhuo Wang
Summary: This study selected 2025 epigenetic-related genes and validated 9 lncRNAs associated with DLBCL. The established ELncSig can predict the survival outcomes of DLBCL and is correlated with immune characteristics.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Wenhua Jiang, Hailong Wang, Shiyong Zhou, Guoqing Zhu, Mingyou Gao, Kuo Zhao, Limeng Zhang, Xiaojing Xie, Ning Zhao, Caijuan Tian, Zhenzhen Zhang, Fang Yan, Yi Pan, Pengfei Liu
Summary: This study constructed a new typing model for DLBCL based on BCR repertoire sequencing, which can better predict survival time after chemotherapy. FTSJ3, MAGED2, and ODF3L2 may represent key genes for the difference in prognosis between the two clusters.
Review
Hematology
Eliza A. Hawkes, Allison Barraclough, Laurie H. Sehn
Summary: Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype, has a good prognosis in limited-stage DLBCL (LS-DLBCL) patients. Recent studies have provided new insights and strategies for the treatment of LS-DLBCL, including the use of PET scans and clinical trials. However, there is currently no standard definition for LS-DLBCL, and treatment strategies vary across studies, posing challenges in interpretation.